News

In 1993, Jayafilake et al. showed that both trans-resveratrol and cis-resveratrol have anticancer activity because they can inhibit the activity of protein-tyrosine kinases. Jang and other research groups further pointed out that resveratrol has great anti-cancer activity in the three stages of cancer occurrence, namely initiation, promotion and development, and has inhibitory and even reversal effects on the three stages of cancer occurrence. :

1. Inhibition of initiation. Reduce the formation of free radicals, induce the increase of phase II pharmacokinetic enzymes, and antagonize the effect of dioxins;

2. inhibit the promotion. Inhibit cyclooxygenase (COX), inhibit catalase;

3. inhibit development. Inhibits cancer cell proliferation, induces cancer cell differentiation, and induces cancer cell apoptosis. Resveratrol is expected to act as an inhibitor of protein tyrosine kinase PTK. Many medical studies have found that resveratrol has obvious inhibitory effects on breast cancer, gastric cancer, colon cancer, prostate cancer, leukemia, ovarian cancer, skin cancer and other malignant tumor cells.

In January 1997, a research team led by Professor John Pezzuto from the School of Pharmacy, University of Illinois, Chicago, published a report entitled "Anti-cancer activity of natural product resveratrol from grapes" in the famous American journal "Science". The paper caused a sensation in the medical science community. The paper proves that resveratrol can effectively inhibit the cellular activities associated with various cancer processes.

As an antioxidant, antimutagenic and anti-inflammatory agent, resveratrol has shown chemopreventive properties against cancer. It can prevent cell cancerous lesions and prevent the spread of malignant tumors, and it can also inhibit protein chromine kinase, which has an anti-mutagenic effect by blocking the function of the kinase.